| abstract |
The present invention relates to 6-5 membered fused pyridine ring compounds of formula (I) or pharmaceutically acceptable salts thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. Specifically, the present invention relates to the use of a 6-5 membered fused pyridine ring compound of formula (I) in the treatment of a Breton tyrosine kinase (Btk) mediated disorder. [Chemical 1] |